BioCentury | Jun 29, 2009
Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

...FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 6-1 that Rejena from Lantibio did not demonstrate...
...U.S. rights to commercialize Rejena. TRB, which markets the product as Vismed in Europe, granted Lantibio...
...and market it to treat dry eye syndrome in 2006 (see BioCentury, Jan. 16, 2006). Lantibio...
BioCentury | Jun 27, 2009
Company News

FDA panel backs Bepreve, rebuffs Rejena

...$0.45 (11%) to $4.69. The committee also voted 6-1 that Rejena (formerly Vismed ) from Lantibio...
BioCentury | Jun 8, 2009
Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

...and Ophthalmic Drugs Advisory Committee will meet on June 26 to discuss an NDA from Lantibio...
...is a 0.18% sodium hyaluronate ophthalmic solution. TRB, which markets the product in Europe, granted Lantibio...
...U.S. rights to commercialize Vismed to treat dry eye syndrome (see BioCentury, Nov. 12, 2007). Lantibio...
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...stem cell therapy delivered using plasma polymerization technology Nov 07 Lantibio/Alcon (NYSE:ACL)/ TRB Chemedica Undisclosed Lantibio...
BioCentury | Nov 12, 2007
Company News

Lantibio, TRB Chemedica, Alcon Laboratories Inc. deal

...in Phase III testing for the indication. Lantibio plans to submit an NDA next year. Lantibio...
...also is eligible for royalties from Alcon. TRB, which markets the product in Europe, granted Lantibio...
...exclusive U.S. rights to develop and market Vismed in 2006 (see BioCentury, Jan. 16, 2006). Lantibio...
BioCentury | Mar 12, 2007
Clinical News

Duramycin: Phase II data

...year. AOP licensed the development rights from Lantibio. AOP Orphan Pharmaceuticals AG , Vienna, Austria Lantibio...
BioCentury | Jan 22, 2007
Clinical News

Vismed: Phase III started

...FDA. Last year, Lantibio licensed Vismed from TRB Chemedica, which markets the product in Europe. Lantibio...
BioCentury | Jan 16, 2006
Company News

Lantibio Inc., TRB Chemedica International SA deal

...TRB granted Lantibio exclusive U.S. rights to develop and market Vismed to treat dry eye syndrome...
...to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio...
...of the sodium hyaluronate product in the U.S. this year. TRB markets Vismed in Europe. Lantibio...
BioCentury | Jan 13, 2006
Company News

Lantibio in-licenses TRB's Vismed

...TRB Chemedica (Geneva, Switzerland) granted Lantibio (Chapel Hill, N.C.) exclusive U.S. rights to develop and market...
...to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio...
...of the sodium hyaluronate product in the U.S. this year. TRB markets Vismed in Europe. Lantibio...
BioCentury | Aug 22, 2005
Company News

Lantibio Inc., Apotex Fermentation Inc. deal

...Apotex will produce clinical and commercial batches of Lantibio's Moli1901 in exchange for royalties. The polycyclic...
...antibiotic is in Phase I testing to treat dry eye syndrome and cystic fibrosis (CF). Lantibio Inc....
Items per page:
1 - 10 of 12
BioCentury | Jun 29, 2009
Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

...FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 6-1 that Rejena from Lantibio did not demonstrate...
...U.S. rights to commercialize Rejena. TRB, which markets the product as Vismed in Europe, granted Lantibio...
...and market it to treat dry eye syndrome in 2006 (see BioCentury, Jan. 16, 2006). Lantibio...
BioCentury | Jun 27, 2009
Company News

FDA panel backs Bepreve, rebuffs Rejena

...$0.45 (11%) to $4.69. The committee also voted 6-1 that Rejena (formerly Vismed ) from Lantibio...
BioCentury | Jun 8, 2009
Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

...and Ophthalmic Drugs Advisory Committee will meet on June 26 to discuss an NDA from Lantibio...
...is a 0.18% sodium hyaluronate ophthalmic solution. TRB, which markets the product in Europe, granted Lantibio...
...U.S. rights to commercialize Vismed to treat dry eye syndrome (see BioCentury, Nov. 12, 2007). Lantibio...
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...stem cell therapy delivered using plasma polymerization technology Nov 07 Lantibio/Alcon (NYSE:ACL)/ TRB Chemedica Undisclosed Lantibio...
BioCentury | Nov 12, 2007
Company News

Lantibio, TRB Chemedica, Alcon Laboratories Inc. deal

...in Phase III testing for the indication. Lantibio plans to submit an NDA next year. Lantibio...
...also is eligible for royalties from Alcon. TRB, which markets the product in Europe, granted Lantibio...
...exclusive U.S. rights to develop and market Vismed in 2006 (see BioCentury, Jan. 16, 2006). Lantibio...
BioCentury | Mar 12, 2007
Clinical News

Duramycin: Phase II data

...year. AOP licensed the development rights from Lantibio. AOP Orphan Pharmaceuticals AG , Vienna, Austria Lantibio...
BioCentury | Jan 22, 2007
Clinical News

Vismed: Phase III started

...FDA. Last year, Lantibio licensed Vismed from TRB Chemedica, which markets the product in Europe. Lantibio...
BioCentury | Jan 16, 2006
Company News

Lantibio Inc., TRB Chemedica International SA deal

...TRB granted Lantibio exclusive U.S. rights to develop and market Vismed to treat dry eye syndrome...
...to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio...
...of the sodium hyaluronate product in the U.S. this year. TRB markets Vismed in Europe. Lantibio...
BioCentury | Jan 13, 2006
Company News

Lantibio in-licenses TRB's Vismed

...TRB Chemedica (Geneva, Switzerland) granted Lantibio (Chapel Hill, N.C.) exclusive U.S. rights to develop and market...
...to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio...
...of the sodium hyaluronate product in the U.S. this year. TRB markets Vismed in Europe. Lantibio...
BioCentury | Aug 22, 2005
Company News

Lantibio Inc., Apotex Fermentation Inc. deal

...Apotex will produce clinical and commercial batches of Lantibio's Moli1901 in exchange for royalties. The polycyclic...
...antibiotic is in Phase I testing to treat dry eye syndrome and cystic fibrosis (CF). Lantibio Inc....
Items per page:
1 - 10 of 12